Log In
Print
BCIQ
Print
Print this Print this
 

SAN-300

  Manage Alerts
Collapse Summary General Information
Company Salix Pharmaceuticals Ltd.
DescriptionAnti-VLA-1 mAb
Molecular Target Integrin alpha(1)beta(1) (VLA-1) (ITGA1) (CD49a/CD29)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation

Partner

Biogen Idec Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today